Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Scientific Advisory Board
    • Pipeline
    • Grants
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Newsroom

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
Mar 31, 2026
PDF Version
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
Mar 30, 2026
PDF Version
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Mar 17, 2026
PDF Version
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Mar 16, 2026
PDF Version
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 10, 2026
PDF Version
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


 
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

 
Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

 

Email Alerts

  • OUR COMPANY
  • About Us
  • Leadership Team
  • Board of Directors
  • Ethics and Compliance
  • Corporate Governance & Committee Composition
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Scientific Advisory Board
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • INVESTORS & MEDIA
  • Overview
  • Newsroom
  • Events
  • Financial Information
  • Stock Information & Analyst Coverage
  • FAQs
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors